Zanubrutinib is under clinical development by BeiGene and currently in Phase II for Unspecified B-Cell Lymphomas.

Vactosertib is under clinical development by MedPacto and currently in Phase I for Acute Lymphoblastic Lymphoma.

进一步的研究表明，米替福新改善的衰竭T细胞的效应功能，减少了衰竭，挽救了它们的糖酵解和氧化磷酸化（OXPHOS）代谢缺陷，从而提高了治疗实体瘤的疗效。他们还发现米替福新以GLUT1依赖的方式促进功能低下的CAR-T细胞中的葡萄糖可用性，从而改善它们的效应功能。

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects white blood cells (WBCs). Since these blood cells are part of the immune system, CLL affects the body’s ability to fight germs.

A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton ...

During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed ...

Amgen’s Blincyto (blinatumomab) has been granted a licence extension by the Medicines and Healthcare products Regulatory ...